Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) shares rose 3.4% during trading on Monday . The stock traded as high as $1.86 and last traded at $1.85. Approximately 3,706 shares were traded during trading, a decline of 66% from the average daily volume of 10,945 shares. The stock had previously closed at $1.79.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH began coverage on Anebulo Pharmaceuticals in a research note on Wednesday, July 27th. They issued a "buy" rating and a $6.00 price target for the company.
Get Anebulo Pharmaceuticals alerts:Anebulo Pharmaceuticals Price Performance
The stock's 50-day moving average price is $3.07 and its 200-day moving average price is $3.55.
Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Rating) last issued its quarterly earnings results on Friday, September 9th. The company reported ($0.10) EPS for the quarter. Equities research analysts forecast that Anebulo Pharmaceuticals, Inc. will post -0.51 earnings per share for the current fiscal year.Institutional Investors Weigh In On Anebulo Pharmaceuticals
An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. LVW Advisors LLC acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 700,000 shares of the company's stock, valued at approximately $3,640,000. LVW Advisors LLC owned 3.00% of Anebulo Pharmaceuticals as of its most recent SEC filing. 20.04% of the stock is owned by institutional investors and hedge funds.
About Anebulo Pharmaceuticals
(Get Rating)
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
Featured Articles
- Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
- Kimberly-Clark Products Post Weak Quarter Despite Raising Prices
- Why is Kraft Heinz Stock Moving Higher? It's a Great Bargain
- Is This The Bottom For Canopy Growth Corporation?
- Solar-Industry Small Cap Array Set For Big EPS Growth In 2023
- Unity Software is the Other Video Game Engine To Watch
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.